Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis Sho ShiinoGraham BallEmad A. Rakha Review Open access 06 October 2021 Pages: 1 - 14
Novel classes of immunotherapy for breast cancer Alberto Hernando-CalvoDavid W. CesconPhilippe L. Bedard Review 08 October 2021 Pages: 15 - 29
Penetrance of male breast cancer susceptibility genes: a systematic review Reem S. ChamseddineCathy WangKevin S. Hughes Review 13 October 2021 Pages: 31 - 38
Biomarkers of immunotherapy response in breast cancer beyond PD-L1 Nuria ChicFara Brasó-MaristanyAleix Prat Review 21 October 2021 Pages: 39 - 49
A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation Lei HuangRuiqin WangJianmin Fang Preclinical study 16 October 2021 Pages: 51 - 61
KIF21A regulates breast cancer aggressiveness and is prognostic of patient survival and tumor recurrence Anton J. LucanusAye Aye ThikeGeorge W. Yip Preclinical study 26 October 2021 Pages: 63 - 75
Breast reconstruction is a viable option for older patients Utku C. DolenJody LawTerence M. Myckatyn Clinical trial 05 October 2021 Pages: 77 - 86
Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients Lotte PoulsenManraj KaurJens A. Sørensen Clinical trial 13 October 2021 Pages: 87 - 96
Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up Fangchao ZhengFeng DuPeng Yuan Clinical trial 14 October 2021 Pages: 97 - 105
SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study Jennifer L. BakerFarnaz HajiMaggie L. DiNome Clinical trial 15 October 2021 Pages: 107 - 114
Elevated magnetic resonance imaging measures of adipose tissue deposition in women with breast cancer treatment-related lymphedema Rachelle CrescenziPaula M. C. DonahueManus J. Donahue Clinical trial 23 October 2021 Pages: 115 - 124
Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN Ellen B. GoldSybil L. CrawfordNancy E. Avis Epidemiology Open access 25 October 2021 Pages: 125 - 135
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis Nadia BiancoMonica MilanoGiuseppe Viale Epidemiology 05 October 2021 Pages: 137 - 145
Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa) Hiltrud MerzenichDan BaakenHeinz Schmidberger Epidemiology Open access 09 October 2021 Pages: 147 - 157
Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li–Fraumeni syndrome Atara SiegelRenee C. BremerPayal P. Khincha Epidemiology 15 October 2021 Pages: 159 - 167
Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis Lifen CaoRobert ShenkAlberto J. Montero Epidemiology 16 October 2021 Pages: 169 - 176
Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield Tracy OnegaWeiwei ZhuDiana S. M. Buist Epidemiology 22 October 2021 Pages: 177 - 190
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer Pauline CorbauxAudrey Lardy-CleaudThomas Bachelot Epidemiology 23 October 2021 Pages: 191 - 207
The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs Matthew N. MillsThrisha K. PotluriKamran A. Ahmed Brief Communication 20 October 2021 Pages: 209 - 217
Omitting axillary dissection: could we offer a more tailored management to elderly patients with breast cancer? Andrés VargasKatarzyna HolubAlbert Biete Letter to the Editor 05 October 2021 Pages: 219 - 220
Correction to: Breast cancer, diabetes mellitus and glucagon‑like peptide‑1 receptor toward exploring their possible associations Naoko Hashimoto TakigamiShimpei KuniyoshiHironobu Sasano Correction 04 October 2021 Pages: 221 - 221
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population Michelino De LaurentiisSimona BorstnarClaudio Zamagni Correction Open access 08 October 2021 Pages: 223 - 224
Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) Noam PondéDominique Agbor‑TarhMartine Piccart Correction 08 October 2021 Pages: 225 - 225
Correction to: Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer Megan RenAnali OrozcoMichael Dean Correction 09 November 2021 Pages: 227 - 227
